Selected article for: "epithelial cell and primary cell"

Author: Chan, Renee W. Y.; Poon, Leo L. M.
Title: The Emergence of Human Coronavirus EMC: How Scared Should We Be?
  • Document date: 2013_4_9
  • ID: kna8kca6_8
    Snippet: Based on the lack of IFN response found upon HCoV-EMC infection in HAE cultures, Kindler et al. conducted a key experiment and demonstrated the effective suppression of HCoV-EMC replication by administration of type I or type III IFN in the cultures. Zielecki et al. have recently confirmed that HCoV-EMC is sensitive to the antiviral action of type I IFN by using primary non-differentiated tracheobronchial epithelial cells and other epithelial cel.....
    Document: Based on the lack of IFN response found upon HCoV-EMC infection in HAE cultures, Kindler et al. conducted a key experiment and demonstrated the effective suppression of HCoV-EMC replication by administration of type I or type III IFN in the cultures. Zielecki et al. have recently confirmed that HCoV-EMC is sensitive to the antiviral action of type I IFN by using primary non-differentiated tracheobronchial epithelial cells and other epithelial cell lines (11) . Again, the confirmation of IFN effectiveness in other models, particularly those relevant to lower respiratory tract infections, will strengthen the use of IFN as a possible therapeutic strategy to control HCoV-EMC infection. Nonetheless, Kindler et al. have pointed out a promising therapy for treating HCoV-EMC infection.

    Search related documents:
    Co phrase search for related documents
    • antiviral action and therapeutic strategy: 1, 2, 3
    • antiviral action and tract infection: 1, 2, 3
    • cell line and respiratory tract infection: 1, 2, 3, 4
    • cell line and respiratory tract infection lower: 1
    • cell line and therapeutic strategy: 1, 2, 3, 4, 5, 6, 7
    • cell line and tract infection: 1, 2, 3, 4, 5
    • cell line and type administration: 1
    • effective suppression and therapeutic strategy: 1
    • epithelial cell and respiratory tract infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • epithelial cell and respiratory tract infection lower: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • epithelial cell and therapeutic strategy: 1, 2, 3, 4
    • epithelial cell and tracheobronchial epithelial cell: 1
    • epithelial cell and tract infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • epithelial cell and type administration: 1
    • epithelial cell line and respiratory tract infection: 1, 2, 3
    • epithelial cell line and respiratory tract infection lower: 1
    • epithelial cell line and therapeutic strategy: 1, 2
    • epithelial cell line and tract infection: 1, 2, 3
    • HCoV emc and respiratory tract infection: 1, 2, 3